Anbio Biotechnology Limited is a healthcare technology company specializing in the development and manufacturing of advanced in vitro diagnostic (IVD) products. Established in 2021, the company’s primary focus is to revolutionize diagnostics by delivering innovative solutions that support personalized and decentralized patient care. Anbio Biotechnology offers a comprehensive portfolio of diagnostic products, including chemiluminescence immunoassays, lateral flow immunoassays, fluorescent immunoassays, polymerase chain reaction tests, and loop-mediated isothermal amplification. These platforms are designed for use in over-the-counter, point-of-care, and laboratory settings, facilitating rapid and accurate detection of a wide range of biomarkers related to infectious diseases, cancer, cardiovascular disorders, inflammation, drug abuse, endocrine and renal conditions, pharmacogenomics, and diabetes. By providing accessible and efficient diagnostic tools compatible with diverse sample types, such as blood, urine, saliva, and more, Anbio Biotechnology plays a vital role in enabling earlier intervention and improved health outcomes. The company serves healthcare providers and patients globally, responding to the rising demand for effective diagnostics and supporting the ongoing evolution toward precision medicine and decentralized healthcare delivery.